Design of a broadly reactive Lyme disease vaccine
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F20%3A00538263" target="_blank" >RIV/60077344:_____/20:00538263 - isvavai.cz</a>
Result on the web
<a href="https://www.nature.com/articles/s41541-020-0183-8" target="_blank" >https://www.nature.com/articles/s41541-020-0183-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41541-020-0183-8" target="_blank" >10.1038/s41541-020-0183-8</a>
Alternative languages
Result language
angličtina
Original language name
Design of a broadly reactive Lyme disease vaccine
Original language description
A growing global health concern, Lyme disease has become the most common tick-borne disease in the United States and Europe. Caused by the bacterial spirochete Borrelia burgdorferi sensu lato (sl), this disease can be debilitating if not treated promptly. Because diagnosis is challenging, prevention remains a priority, however, a previously licensed vaccine is no longer available to the public. Here, we designed a six component vaccine that elicits antibody (Ab) responses against all Borrelia strains that commonly cause Lyme disease in humans. The outer surface protein A (OspA) of Borrelia was fused to a bacterial ferritin to generate self-assembling nanoparticles. OspA-ferritin nanoparticles elicited durable high titer Ab responses to the seven major serotypes in mice and non-human primates at titers higher than a previously licensed vaccine. This response was durable in rhesus macaques for more than 6 months. Vaccination with adjuvanted OspA-ferritin nanoparticles stimulated protective immunity from both B. burgdorferi and B. afzelii infection in a tick-fed murine challenge model. This multivalent Lyme vaccine offers the potential to limit the spread of Lyme disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
npj Vaccines
ISSN
2059-0105
e-ISSN
—
Volume of the periodical
5
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
33
UT code for WoS article
000529758700001
EID of the result in the Scopus database
2-s2.0-85084150407